Anemia with menorrhagia: Ferric carboxymaltose a safer alter
According to a recently published study, intravenous FCM (ferric carboxymaltose) is an effective and a safe treatment option for patients of menorrhagia. presenting with iron deficiency anemia (IDA) with a single administration of high dose without serious adverse effects obviating the need for blood transfusion before surgery.

The objective of the study was to evaluate the safety and efficacy of FCM in treating anemia in patients of menorrhagia. Thus avoiding blood transfusion.

The study included 90 women of age more than 30 years with definitive diagnosis of menorrhagia with IDA and hemoglobin (Hb) levels between 4 gm% and 11 gm%. Intravenous FCM (500–1500 mg) was administered, and the improvement in blood indices was assessed after 3 weeks of total dose infusion. Menorrhagia was controlled by medical treatment till Hb improvement was achieved and definitive surgical intervention was done.

Blood indices measured pre-FCM and 3 weeks post-FCM showed a statistically significant mean increase in Hb from 8.33 to 10.89. There was a statistically significant rise of packed cell volume, serum ferritin, and serum iron in the post-FCM blood levels after 3 weeks. No serious life-threatening adverse events were observed after FCM administration.

Read in detail here:;year=2018;volume=9;issue=2;spage=92;epage=96;aulast=Mishra
Dr. v●●●d c●●●●a and 1 others like this1 share